 Home > Active Ingredient News > Antitumor Therapy > Lancet Oncol: Carrelizumab combined with apatinib is expected to be a salvage treatment plan for chemotherapy-refractory/recurrent gestational trophoblastic tumors!

Lancet Oncol: Carrelizumab combined with apatinib is expected to be a salvage treatment plan for chemotherapy-refractory/recurrent gestational trophoblastic tumors!

 Last Update: 2021-10-20
 Source: Internet
 Author: User

Tags

hydrochlorothiazide 50 mg

hib treatment

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

There are limited treatment options for high-risk patients with chemotherapy-refractory or recurrent gestational trophoblastic tumors
.

The synergistic anti-tumor effect of immunotherapy and anti- angiogenic drugs has been confirmed in a variety of solid tumors

Immune blood vessel

This is a single-center, open-label phase 2 trial carried out in a Beijing tertiary hospital, recruiting 18-70 year olds who have received at least second-line multi-drug chemotherapy in the past for high-risk chemotherapy-refractory or recurrent gestational trophoblastic tumors The patient was treated with carrelizumab (200 mg/2 weeks) + apatinib (250 mg/day) until the disease progressed or intolerable toxicity appeared
.

The primary endpoint is the objective response rate

Treatment response

From August 7, 2019 to March 18, 2020, a total of 20 patients were recruited, of which 19 (95%) were diagnosed with choriocarcinoma (or choriocarcinoma), and the other (5%) was diagnosed with Trophoblastic tumors in the placenta
.

The median follow-up was 18.

All in all, the combination of carrelizumab and apatinib has shown expected anti-tumor activity and acceptable safety in high-risk chemotherapy-refractory or recurrent gestational trophoblastic tumor patients, or can be used as such The patient's rescue treatment options

Carrelizumab combined with apatinib has demonstrated expected anti-tumor activity and acceptable safety in high-risk chemotherapy-refractory or recurrent gestational trophoblastic tumor patients, or it can be used as a good option for such patients.

Original source:

Hongyan Cheng, et al.

Camrelizumab plus apatinib in patients with high- risk chemorefractory or relapsed gestational trophoblastic neoplasia (CAP 01): a single-arm, open-label, phase 2 trial in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.